Last reviewed · How we verify
NCT05608577: RE-BLEED
RE-BLEED: A Digital Platform for Identifying Bleeding Patients - a Feasibility Study
trial in Hemorrhage in 40 participants. Completed in 18 February 2026.
18 February 2026
Quick facts
| Lead sponsor | University of Oxford |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 40 |
| Start date | 1 October 2021 |
| Primary completion | 18 February 2026 |
| Estimated completion | 18 February 2026 |
| Sites | 1 location across United Kingdom |
Conditions studied
- Hemorrhage — all drugs for Hemorrhage →
- Trauma — all drugs for Trauma →
- Gastro Intestinal Bleeding — all drugs for Gastro Intestinal Bleeding →
Sponsor
University of Oxford
Who can join
Adults 16 to 110, any sex, with Hemorrhage or Trauma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The RE-BLEED feasibility study aims to develop and test a real-time digital platform, whereby bleeding patients in-hospital can be identified and approached for their consent to participate in future research studies.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05608577
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hemorrhage
Currently open trials in the same condition.
- NCT07311343 — Oral Hygiene and Prophylactic Antibiotics to Prevent Intracerebral Hemorrhage Associated Pneumonia · Phase 4 · recruiting
- NCT07105904 — Biological and Clinical Relevance of Quantra Viscoelastic Hemostatic Assay in Hemorrhagic Cardiac Surgery · active not recruiting
- NCT06979466 — Q Therapeutic System for Chronic Stroke Recovery · NA · recruiting
- NCT06664775 — A Study to Compare the Efficacy and Safety of TachoSil and Surgicel Original as an Adjunct to Control Mild to Moderate S · Phase 3 · recruiting
- NCT06304714 — Effects of Bothrops Spp. Snake Envenomation on Willebrand Factor Activity in Martinique and French Guiana · recruiting
Other University of Oxford trials
Trials by the same sponsor.
- NCT05380388 — A Safety, Immunogenicity and Efficacy Study of PvRII/Matrix-M in Healthy Thai Adults Living in Thailand ( MIST3 ) · Phase 2 · not yet recruiting
- NCT07470424 — A Clinical Study of Piperaquine, Pyronaridine, and Artesunate Administered in Combination in Healthy Adults · Phase 1 · not yet recruiting
- NCT07345910 — Environment, Pathogens, and Host Interactions in Melioidosis · not yet recruiting
- NCT07434973 — Stratification and Treatment in Early Psychosis Study - PROMOTE · Phase 3 · not yet recruiting
- NCT07460401 — 'Do Patient Characteristics Associate With Poor Outcome With Femoral Acetabular Impingement Syndrome (FAIS) Following Ph · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05608577 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Oxford
- Last refreshed: 20 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05608577.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing